B-cell overexpression of Bcl-2 cooperates with p21 deficiency for the induction of autoimmunity and lymphomas

Journal of Autoimmunity

Volumn 35, Issue 4, 2010, Pages 316-324

  Santiuste, Inés ^a   Buelta, Luis ^a   Iglesias, Marcos ^a   Genre, Fernanda ^a   Mazorra, Francisco ^b   Izui, Shozo ^c   Merino, Jesús ^a   Merino, Ramón ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

B cell lymphomas; Bcl 2; P21WAF1 Cip1; P27kip1; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; CD4 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEIN BCL 2; PROTEIN P21;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; GLOMERULAR DYSFUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INCIDENCE; LETHALITY; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; TRANSGENIC MOUSE;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE MODELS, ANIMAL; EPISTASIS, GENETIC; HUMANS; IMMUNOLOGIC MEMORY; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSGENES;

EID: 77958153383     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2010.07.002     Document Type: Article

References (40)

1. Goodnow C.C. Multistep pathogenesis of autoimmune disease. Cell 2007, 130:25-35.
2. Marquina R., Díez M.A., López-Hoyos M., Buelta L., Kuroki A., Kikuchi S., et al. Inhibition of B cell death causes the development of an IgA nephropathy in (New Zealand white x C57BL/6)F(1)-bcl-2 transgenic mice. J Immunol 2004, 172:7177-7185.
3. Strasser A., Whittingham S., Vaux D.L., Bath M.L., Adams J.M., Cory S., et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 1991, 88:8661-8665.
4. Bouillet P., Metcalf D., Huang D.C., Tarlinton D.M., Kay T.W., Köntgen F., et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999, 286:1735-1738.
5. Bouillet P., Cory S., Zhang L.C., Strasser A., Adams J.M. Degenerative disorders caused by Bcl-2 deficiency are prevented by loss of its BH3-only antagonist Bim. Dev Cell 2001, 1:645-653.
6. Vidal S., Kono D.H., Theofilopoulos A.N. Loci predisposing to autoimmunity in MRL-Fas lpr and C57BL/6-Fas lpr mice. J Clin Invest 1998, 101:696-702.
7. Balomenos D., Martín-Caballero J., García M.I., Prieto I., Flores J.M., Serrano M., et al. The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. Nat Med 2000, 6:171-176.
8. Goulvestre C., Chéreau C., Nicco C., Mouthon L., Weill B., Batteux F. A mimic of p21WAF1/CIP1 ameliorates murine lupus. J Immunol 2005, 175:6959-6967.
9. Arias C.F., Ballesteros-Tato A., García M.I., Martín-Caballero J., Flores J.M., Martínez-A C., et al. p21CIP1/WAF1 controls proliferation of activated/memory T cells and affects homeostasis and memory T cell responses. J Immunol 2007, 178:2296-2306.
10. Lawson B.R., Kono D.H., Theofilopoulos A.N. Deletion of p21 (WAF-1/Cip1) does not induce systemic autoimmunity in female BXSB mice. J Immunol 2002, 168:5928-5932.
11. Lawson B.R., Baccala R., Song J., Croft M., Kono D.H., Theofilopoulos A.N. Deficiency of the cyclin kinase inhibitor p21(WAF-1/CIP-1) promotes apoptosis of activated/memory T cells and inhibits spontaneous systemic autoimmunity. J Exp Med 2004, 199:547-557.
12. Santiago-Raber M.L., Lawson B.R., Dummer W., Barnhouse M., Koundouris S., Wilson C.B., et al. Role of cyclin kinase inhibitor p21 in systemic autoimmunity. J Immunol 2001, 167:4067-4074.
13. Boussiotis V.A., Freeman G.J., Taylor P.A., Berezovskaya A., Grass I., Blazar B.R., et al. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med 2000, 6:290-297.
14. Li L., Iwamoto Y., Berezovskaya A., Boussiotis V.A. A pathway regulated by cell cycle inhibitor p27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance. Nat Immunol 2006, 7:1157-1165.
15. Fero M.L., Rivkin M., Tasch M., Porter P., Carow C.E., Firpo E., et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996, 85:733-744.
16. Tsujimoto Y., Croce C.M. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A 1986, 83:5214-5218.
17. McDonnell T.J., Korsmeyer S.J. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 1991, 349:254-256.
18. Strasser A., Harris A.W., Cory S. E-mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells. Oncogene 1993, 8:1-9.
19. Bhatia K., Fan S., Spangler G., Weintraub M., O'Connor P.M., Judde J.G., et al. mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma. Cancer Res 1995, 55:1431-1435.
20. Martín-Caballero J., Flores J.M., García-Palencia P., Serrano M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res 2001, 61:6234-6238.
21. Cheng N., van de Wetering C.I., Knudson C.M. p27 deficiency cooperates with Bcl-2 but not Bax to promote T-cell lymphoma. PLoS One 2008, 3. e1911.
22. Brugarolas J., Chandrasekaran C., Gordon J.I., Beach D., Jacks T., Hannon G.J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995, 377:552-557.
23. + T cell-dependent inhibition of autoimmunity in transgenic mice overexpressing human Bcl-2 in T lymphocytes. J Immunol 2007, 178:2778-2786.
24. Grillot D.A., Merino R., Pena J.C., Fanslow W.C., Finkelman F.D., Thompson C.B., et al. bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice. J Exp Med 1996, 183:381-391.
25. López-Hoyos M., Carrió R., Merino R., Buelta L., Izui S., Núñez G., et al. Constitutive expression of bcl-2 in B cells causes a lethal form of lupuslike autoimmune disease after induction of neonatal tolerance to H-2b alloantigens. J Exp Med 1996, 183:2523-2531.
26. Merino R., Iwamoto M., Gershwin M.E., Izui S. The Yaa gene abrogates the major histocompatibility complex association of murine lupus in (NZB x BXSB)F1 hybrid mice. J Clin Invest 1994, 94:521-525.
27. Izui S., Higaki M., Morrow D., Merino R. The Y chromosome from autoimmune BXSB/MpJ mice induces a lupus-like syndrome in (NZW x C57BL/6)F1 male mice, but not in C57BL/6 male mice. Eur J Immunol 1988, 18:911-915.
28. Maddika S., Ande S.R., Panigrahi S., Paranjothy T., Weglarczyk K., Zuse A., et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 2007, 10:13-29.
29. Huang D.C., O'Reilly L.A., Strasser A., Cory S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 1997, 16:4628-4638.
30. Vairo G., Soos T.J., Upton T.M., Zalvide J., DeCaprio J.A., Ewen M.E., et al. Bcl-2 retards cell cycle entry through p27(Kip1), pRB relative p130, and altered E2F regulation. Mol Cell Biol 2000, 20:4745-4753.
31. Rowell E.A., Wang L., Hancock W.W., Wells A.D. The cyclin-dependent kinase inhibitor p27kip1 is required for transplantation tolerance induced by costimulatory blockade. J Immunol 2006, 177:5169-5176.
32. Marín M.J., García I., Peña M., Bolívar A., Zubiaga A., López-Hoyos M. E2F1-/- C57BL/6 mice overexpressing a human Bcl-2 transgene in B cells develop a mild autoimmune syndrome. Ann N Y Acad Sci 2005, 1051:156-165.
33. Marín-Vidalled M.J., Bolívar A., Zubiaga A., López-Hoyos M. The combined effect of BCL-2 over-expression and E2F2 deficiency induces an autoimmune syndrome in non-susceptible mouse strain C57BL/6. Autoimmunity 2010, 43:111-120.
34. Nuñez G., Hockenbery D., McDonnell T.J., Sorensen C.M., Korsmeyer S.J. Bcl-2 maintains B cell memory. Nature 1991, 353:71-73.
35. Hande S., Notidis E., Manser T. Bcl-2 obstructs negative selection of autoreactive, hypermutated antibody V regions during memory B cell development. Immunity 1998, 8:189-198.
36. Fischer S.F., Bouillet P., O'Donnell K., Light A., Tarlinton D.M., Strasser A. Proapoptotic BH3-only protein Bim is essential for developmentally programmed death of germinal center-derived memory B cells and antibody-forming cells. Blood 2007, 110:3978-3984.
37. Bielschowsky M., Bielschowsky F. Reaction of the reticular tissue of mice with autoimmune haemolytic anaemia to 2-aminofluorene. Nature 1962, 194:692.
38. Marti G.E., Metcalf R.A., Raveche E. The natural history of a lymphoproliferative disorder in aged NZB mice. Curr Top Microbiol Immunol 1995, 194:117-126.
39. Davidson W.F., Giese T., Fredrickson T.N. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med 1998, 187:1825-1838.
40. Airoldi I., Di Carlo E., Cocco C., Sorrentino C., Fais F., Cilli M., et al. Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood 2005, 106:3846-3853.